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Abstract
Background: The genetic background to bipolar disorder (BPD) has been
attributed to different genetic and genomic risk factors. In the present study
we hypothesized that inherited copy number variations (CNVs) contribute to
susceptibility of BPD. We screened 637 BP-pedigrees from the NIMH Genetic
Initiative and gave priority to 46 pedigrees. In this subsample we performed
parametric and non-parametric genome-wide linkage analyses using ~21,000
SNP-markers. We developed an algorithm to test for linkage restricted to regions
with CNVs that are shared within and across families.
Results: For the combined CNV and linkage analysis, one region on 19q13
survived correction for multiple comparisons and replicates a previous BPD risk
locus. The shared CNV map to the pregnancy-specific glycoprotein (PSG) gene,
a gene-family not previously implicated in BPD etiology. Two SNPs in the shared
CNV are likely transcription factor binding sites and are linked to expression of
an F-box binding gene, a key regulator of neuronal pathways suggested to be
involved in BPD etiology.
Conclusions: Our CNV-weighted linkage approach identifies a risk locus for BPD
on 19q13 and forms a useful tool to future studies to unravel part of the genetic
vulnerability to BPD.
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Background
Bipolar disorder (BPD) is a burdensome [1] and common [2] spectrum of mental
disorders [3]. The concordance rate which is up to 8.5 times higher for monozygotic
than dizygotic twins for BPD shows that genetic factors contribute to susceptibility to
BPD [4]. Non-genetic factors are however also of importance in the underlying etiology
since the heritability rates are between 59 and 87 % [4]. Accumulating data
demonstrates that BPD is a both clinically and genetically heterogeneous disorder with
different risk factors in different subgroups and with a shared genetic overlap between
different diagnoses of psychiatric disorders [5, 6]. The emerging picture further reveals
that individual genetic risk loci contribute with relatively small effect. This complicated
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picture has for a long time hampered the success to find robust genetic results in BPD.
However, the availability to both larger sample sizes, more dense marker map [7, 8]
and with application of new methodologies enforced by the venture from the
Psychiatric Genomic Consortium (PGC) [9] have finally allowed for statistical robust
signals from the CACNA1C, CACNB2, ODZ4, SYNE1 and NCAN genes.
The genetic architecture of BPD is however more complicated than previously
anticipated [10]. A variety of genomic polymorphisms, not only restricted to variation of
single nucleotides may explain why it has been hard to identify BPD susceptibility genes
[11–13]. This type of variations include larger genomic segments known as copy number
variation (CNV) which, in comparison to a reference genome, are defined as gain or loss of
genomic segments larger than 1 kb in size [13, 14]. It was previously thought that these
forms of genetic polymorphisms are relatively rare and highly potent in conferring
risk [12, 15]. Recent findings indicate that besides the highly penetrant rare risk variants,
common variants also occur but with a more modest risk contribution than previously as-
sumed [12, 16]. An emerging picture thus indicates that different forms of genomic varia-
tions may explain some of the expected genetic risk for a group of individuals [10, 11, 17].
In this study our hypothesis was that CNVs irrespective of their frequencies
predispose to BPD. We further hypothesized that such structural variants are inherited.
Under such assumptions, families ascertained for having high genetic liability of BPD
constitutes an unprecedented opportunity to find such genomic variations in regions
with evidence for linkage. To increase power to find families with linkage to BPD we
screened 637 BP-pedigrees, provided by the NIMH Bipolar Genetic Initiative, and
selected a subsample presumed to carry a genetic form of BPD. Pedigrees were selected
based on family-wise genome-wide linkage analysis or by analyzing candidate genes for
presence of stretches of deletions. We selected 46 BP-pedigrees for our present study
and conducted two separate forms of analyses. First, we performed parametric and
non-parametric genome-wide linkage analyses using a dense SNP-marker map with
genetic data filtered for genotypes mapping to CNVs.
We next tested the same sample with parametric and non-parametric linkage
analyses restricted only to regions with CNVs that are shared among at least two
individuals within the same family. To do this we developed an algorithm to sum family-
wise linkage scores in regions with CNVs that are shared within and across families.
Our results demonstrate that for the linkage part of this study, several signals
surpassed threshold of suggestive linkage for both the non-parametric and parametric
models and confirm several previously reported linkage regions. For the combined
CNV and linkage analysis, one region on 19q13 survived correction for multiple
comparisons and confirms a previously reported risk locus for BPD.
Several plausible candidate genes for BPD reside in 19q13. Moreover, two markers in
the identified CNV have been reported as eQTLs for an F-box binding protein (FBXO30)
with a suggestive role in BPD susceptibility.
Methods
Study subjects and recruitment process
The BP-pedigrees and genotypic data were provided from the NIMH Bipolar Disorder
Genetic Initiative [18] with ascertainment and diagnosis processes conducted during
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1991 to 2001 (Wave 1–4) (detailed described in Additional file 1). This material has
been analyzed for linkage to BPD in previous studies without yielding signals that meet
the criterion of significant linkage (Additional file 1).
Given the complex nature of BPD we applied a screening process intended to select
families presumed to carry a relatively strong genetic influence of risk to BPD (Fig. 1).
In this process genotypic data from 3849 individuals in 637 nuclear and extended
BP-pedigrees was downloaded from the NIMH Genetic Initiatives’ website [19] and
screened with a genome-wide family-wise (defined as the type 1 error for one single family)
parametric linkage scan (microsatellite map, average 10-cM interval) under different gen-
etic models (dominant, recessive, hyper dominant or affected only) using GENEHUNTER
[20] (allele frequencies and penetrance vectors described under linkage analysis).
We followed a common practice for finding linked loci of a complex disorder with an
unclear classification between the different subtypes of the disorder and considered
three affection status models (ASMs) [18].
Fig. 1 Flow chart of analytic strategy. A brief overview of our incremental strategy for finding inherited
CNVs contributing to susceptibility of BPD. The flow chart illustrates our hierarchical two-stage selection
procedure to reduce the entire wave 1–4 pedigree sample from NIMH Bipolar Disorder Genetic Initiative, into a
smaller sample aiming to reduce heterogeneity and increase power to find segregating CNV with risk to BPD.
The two screening methods we applied were a genome-wide family-wise linkage analysis and an analysis for
the presence of stretches of deletions in BP-candidate genes. Calculation for linkage was performed under 3
different affection status models (ASMs). ASM 1: bipolar type 1 and schizoaffective disorder bipolar
type, ASM 2: bipolar type 1 and schizoaffective disorder bipolar type and bipolar type 2, ASM 3:
bipolar type 1 and schizoaffective disorder bipolar type and bipolar type 2 and recurrent depressive disorder.
These analyses intend to ensure that family members were ascertained for having high genetic liability to BPD.
Our selection procedure implies that a subsample of families and family members were selected out of the
entire wave1–4 samples. The main features in marker calling for SNPs (using polymorphic markers) and CNVs
(monomorphic markers) are shown. The flow chart illustrates the two different analyses that were used to test
for inherited CNVs (i) a linkage analysis and (ii) a CNV-weighted linkage analysis which is based on our algorithm
that sum the family-wise linkage scores in regions with CNVs that are shared within and across families. We
addressed the issue with clinical and genetic heterogeneity for risk to BPD by categorizing individuals into 3
different ASMs and tested for parametric linkage under dominant and recessive models, and for non-parametric
(HLOD) linkage
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The criteria we used for selecting BP-pedigrees were a family-wise logarithm of odds
(LOD) score > 1.1, or if several families were found to have overlapping family-wise
LOD scores > 1.0 in the same genomic region. Pedigrees were also screened for
stretches of homozygous genotypes (ROH), possibly indicating deletions, as this type of
genetic polymorphism has been shown to have a suggestive role in the etiology of BPD
[21]. To do this, individuals in Wave1-4 BP-pedigrees were screened for deletions in
SNPs tagging 357 candidate genes for BPD, by scanning for runs of homozygosity and
Mendelian error analysis using the PLINK software [22]. Our ROH-based inclusion
criterion was thus to find larger stretches of deletions in single individuals, and include
the corresponding family regardless of whether deletions occurred in other family
members.
In total we selected 46 families for our analyses consisting of 277 individuals with
DNA and 97 individuals for whom DNA was not available (Additional file 2). We
applied a pre-agreed analysis plan not to report a final result in the present study for a
region that formed inclusion criterion for any family. In absence of interaction, this
eliminates any systematic bias between the removed and retained regions. Table 1
summarizes the pedigree structure for the selected sample (Additional file 3 provides
full details of the 46 pedigrees).





Total number of individuals 366
Number of affected individuals 176
Number of BP-I individuals 168
Number of BP-II individuals 9
Number of SABP individuals 9
Number of RUDD individuals 12
Family size (average) 7.96
Generations (average) 2.74
Number of affected relative pairs ASM1 ASM2 ASM3
1 degree 224 183 200
2 degree 106 99 91
3 degree 33 27 34
4 degree 6 8 10
5 degree 4 3 3
6 degree 2 2 2
Hierarchical affection status models (ASM)
Very narrow affection status model (ASM1) BP-I and SABP
Narrow affection status model (ASM2) BP-I and SABP and BP-II
Broad affection status model (ASM3) BP-I and SABP and BP-II and RUDD
The table displays the summary statistics for the 46 pedigrees under the three different affection status models (ASMs).
BP-I: Bipolar type 1, BP-II: Bipolar type 2, SABP: Schizoaffective bipolar type, RUDD: Recurrent unipolar depressive disorder.
Individuals with a diagnosis of bipolar spectrum disorders that only apply to a certain ASM were coded as “unknown”
under the other ASMs
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Given the complex background of BPD, with clinical and genetic heterogeneities, and
the additional uncertainty in diagnosis classification, we prioritized a smaller sample
rather than a large collection of extended BP-pedigrees in the NIMH Bipolar Disorder
Genetic Initiative wave 1–4. The complex pattern of inheritance in extended pedigrees
complicates detection of segregating risk loci with linkage analysis. In the present
linkage study, we therefore aimed to increase power using one family based criterion
that tends to select pedigrees that are genetically homogeneous, and one ROH criterion
which allows several smaller pedigrees to be chosen.
Genotyping and quality controls
For the final selected individuals DNA samples (lymphoblastoid cells) were obtained from
Rutgers University and Cell Repository (New Jersey, USA) and were genotyped using the
Illumina Human 610quad chip at Uppsala University, Sweden. We applied quality control
(QC) analysis of individuals, SNP and CNV data consisting of an ordered series of steps
to prevent spurious signals that may otherwise mislead statistical inference. Of notice, in
order to reduce the presence of erroneous genotypes, SNPs located within CNV-regions
were removed. Methods of genotyping and QC analysis are described in Additional file 1.
After final QC filter 269 individuals with DNA from 46 pedigrees (44 pedigrees
with Caucasian ancestry and 2 pedigrees with African American ancestry) and 20,714
SNP-markers were ready for the linkage analysis. CNV calling with PennCNV and QC
analysis, as described in the Additional file 1, identified 2806 CNVs (1417 deletions and
1389 duplications). The mean CNV length was 110,455 bp with a maximum and
minimum length of 4,580,011 bp and 10,046 bp respectively.
All of our CNVs overlapped with variations reported in three publicly available
databases in August 2013; Database of Genomic Variants [23], Welcome Trust Sanger
Institute [24] and finally from Children’s Hospital of Philadelphia [25].
Linkage analysis
To unravel a segregating risk locus to BPD in our sample the different levels of heterogen-
eity, both clinical and genetic, prompted us to categorize individuals in different affection
status models (ASMs) and to calculate linkage using multipoint parametric dominant and
recessive models that take into account inter-familial heterogeneity using heterogeneity
LOD scores (HLOD) and multipoint non-parametric models in MERLIN (v.1.1.2) [26].
For the non-parametric analysis we used the linear model [27] with an ‘all affected
relative pairs’ (NPLALL) statistics, in order to identify linkage. The Z scores were
converted to LOD scores and P values according to Kong and Cox 1997 [20]. For the
parametric dominant model we assumed a risk allele frequency of 0.0045 with
penetrance vector 0.001, 0.50 and 0.75 for the three different genotypes, and for the
recessive model we assumed a risk allele frequency of 0.065 with a penetrance vector of
0.0015, 0.0015 and 0.50 [28]. The GENEHUNTER software [20] was used to generate
phased haplotypes and positions of recombinants.
Empirical significance levels for linkage analysis
For the linkage part of this study we defined the suggestive linkage level to be that
which on average would be exceeded by one linkage peak by chance in a genome-wide
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scan, and significant linkage to be that which would be expected to exceed once per 20
genome-wide scans as proposed by Lander and Kruglyak 1995 [29]. To define these
thresholds we simulated 1000 datasets using the MERLIN software in which phenotypic
status and pedigree structure were retained while simulating random multilocus
genotypes. More specifically, these simulations are based on gene dropping in all
pedigrees under the null hypothesis of no linkage. For each pedigree, marker alleles are
first simulated for founders (according to their allele frequencies), then haplotypes are
propagated to all non-founders based on Mendelian segregation and recombinations.
The threshold for the empirical P value corresponding to suggestive linkage was then
calculated based on a family-wise error rate (FWER) of 1-e^{−1} = 0.632, this is the
probability that a Poisson distributed random variable with an expected value of 1, is
positive, and it approximates the probability of at least one significant linkage peak [29].
As the models are nested, correction for multiple comparisons across the different
models would have been too conservative, we corrected only within each model.
Additional file 4 reaffirms that the linkage peaks of all nine models are strongly correlated.
Algorithm of CNV-weighted linkage scores
In order to find inherited genomic regions conferring risk for BPD, the sum of average
family-wise parametric LOD scores or non-parametric Z scores were calculated over
regions and families sharing overlapping CNVs. For families with at least two members
with overlapping CNVs, the average linkage score in the region was calculated and
added to those observed in the same region in other families. Thus, the algorithm
generates a CNV-weighted linkage scores for genomic segments representing regions
with CNVs that are shared within and across families (detailed described in Additional
file 1 and Additional file 5).
Empirical significance levels for CNV-weighted linkage scores
Empirical P values for the CNV-weighted linkage score analyses were also derived by
gene dropping from simulated multilocus genotypes in MERLIN, using the same
marker allele frequencies of the founders as in the unweighted linkage analysis
simulations. For these analyses the threshold for significance was defined based on a
FWER of alpha = 0.05. The nested models made us to correct within each model and
not across the different models. Figure 2 reaffirms that the CNV-weighted linkage
peaks of all nine models are strongly correlated.
Results
Linkage analysis
The multipoint non-parametric (NPLALL) linkage analysis met suggestive level on
3p14.1. The three affection status models generated comparable results with ASM3
exhibiting the strongest peak, NPL Z = 3.56 [20] (Tables 2 and 3 and Additional file 4).
With the parametric dominant model suggestive linkage, HLOD= 2.41, was reached for
the same region (3p14.1) as in the non-parametric model (Table 2 and 3 and Additional
file 4). For the recessive model, the most notable evidence of linkage occurred at
6p12.3 (HLOD = 2.64). Other regions reaching suggestive linkage were 1q23.3 (HLOD=
2.04) and 10q26.2 (HLOD= 2.25), all with ASM3.
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Fig. 2 Results of the genome-wide CNV-weighted linkage analyses. The plots illustrate genome-wide
CNV-weighted linkage scores of the parametric (dominant and recessive) and non-parametric (NPLALL statistics)
models under the three affection status models (ASM1-3). The sum of average family-wise linkage scores LOD
scores for parametric and Z scores for non-parametric models were calculated over regions with the presence
of copy number variation that is shared between at least two individuals within and across families. The
thresholds for significance (dotted lines) were defined after a 1000-fold simulation analysis including
FWER correction
Table 2 Summary table of the suggestive linkage results
Maximum linkage scores of parametric linkage analysis









1 6.2 rs10919096 1q23.3 2.04 (1.97) 0.20 0.95 ASM3 Recessive 0.57 (0.632)
3 4.9 rs1001763 3p14.1 2.41 (1.97) 0.29 0.91 ASM3 Dominant 0.32 (0.632)
6 5.2 rs9381631 6p12.3 2.64 (1.97) 0.28 0.91 ASM3 Recessive 0.19 (0.632)
10 4.5 rs638395 10q26.2 2.25 (1.97) 0.28 0.93 ASM3 Recessive 0.40 (0.632)
The table displays maximum linkage scores for the suggestive linkage results of the non-parametric and parametric
linkage analyses
A 1000-fold simulation analysis generated genome-wide thresholds for suggestive linkage Z and parametric HLOD scores
(shown in parentheses). The approximate 95 % confidence intervals for the highest linkage scores are defined as a LOD-drop,
or Z-drop, corresponding to a unit of 1.0. The mean information content (IC) estimate across all chromosomes was 0.92 (range
0.96–0.70), indicating that most of the genetic information was successfully captured using our high density mapping
approach. The fraction of linked families, alpha, was less than 0.29 for regions showing suggestive linkage, indicating that
there is evidence for a marked heterogeneity with respect to linked loci in these 46 pedigrees
Abbreviations: NPL Z the linkage statistics for the estimation of identity-by-descent (IBD) allele sharing. LOD is the LOD
calculated from NPL Z sores according to Kong and Cox (1997). IC the information content and is a measure of the
probability that the IBD status at a certain locus can be determined for a given pairs of relatives. Alpha a measure of
the locus heterogeneity that indicates the proportion of families with alleles linked to disease at a certain locus.
HLOD estimate of the heterogeneity LOD score. Delta measure of allele sharing among affected individuals within
pedigrees. Empirical P value estimated probability of having a score by chance that is at least as large as the observed
one, after correction for multiple comparisons
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CNV-weighted linkage analysis
We identified 2806 CNVs in our families all of which overlapped with previously
reported CNVs in three publicly available databases (see Materials and Methods).
Of the nine different linkage and affection status models that were tested only the
parametric dominant model, under a narrow diagnose classification (ASM1), exhibited a
significant CNV-weighted linkage score after a 1000-fold simulation analysis including
correction for multiple comparisons, with empirical P = 0.033 (Fig. 2). The significant
signal that exceeded the genome-wide threshold (dashed line of Panel d in Fig. 2) resides
on 19q13 and represents a region of CNVs that due to our algorithm design was divided
into two separate segments (chr19:48066441–48114839 and chr19:48114839–48157656)
(Fig. 3) and was generated from 5 families (Fig. 4a). The positions of each CNV are
provided in Additional file 6. CNVs were present among 12 individuals, 9 of which were
affected under the narrow affection status model (ASM1) in the 5 families contributing to
the CNV weighted linkage score (illustrated in Fig. 3).
The 19q13 region exhibits frequent CNVs in the general population and stretches
over a region that harbors a family of genes encoding the pregnancy-specific
glycoproteins (PSGs) (Fig. 3).
Since the CNV-weighted linkage score analysis did not require a positive CNV status
only among those affected, according to the different affection status models, we next
attempted to find the implications of structural variations in the PSG genes for risk to
BPD. In particular, we wanted to found if the CNVs are de novo or inherited by
performing a haplotype analysis in the families that contributed to the CNV-weighted
linkage peak (Fig. 4a).
In pedigree 29–0174 we observed a deletion in three affected children, but not in the
fourth affected child (29–10534) which otherwise has inherited the same haplotype as
his siblings from the father for whom we did not have any DNA sample. This indicates
either that there is a double crossover in this region or that we missed the detection of
Table 3 Summary table of the suggestive linkage results
Maximum linkage scores of non-parametric linkage analysis
Chr 95 % C.I. (cM) Peak marker Locus NPL Z
(threshold)





3 18.5 rs4855407 3p14.1 3.56 (3.34) 2.34 0.91 0.50 ASM3 0.46 (0.63)
3 3.49 rs4855407 3p14.1 3.49 (3.32) 2.32 0.91 0.49 ASM2 0.48 (0.63)
3 18.5 rs4855407 3p14.1 3.56 (3.30) 2.34 0.91 0.43 ASM1 0.41 (0.63)
The table displays maximum linkage scores for the suggestive linkage results of the non-parametric and parametric
linkage analyses
A 1000-fold simulation analysis generated genome-wide thresholds for suggestive linkage Z and parametric HLOD scores
(shown in parentheses). The approximate 95 % confidence intervals for the highest linkage scores are defined as a LOD-drop,
or Z-drop, corresponding to a unit of 1.0. The mean information content (IC) estimate across all chromosomes was 0.92 (range
0.96–0.70), indicating that most of the genetic information was successfully captured using our high density mapping
approach. The fraction of linked families, alpha, was less than 0.29 for regions showing suggestive linkage, indicating that
there is evidence for a marked heterogeneity with respect to linked loci in these 46 pedigrees
Abbreviations: NPL Z the linkage statistics for the estimation of identity-by-descent (IBD) allele sharing. LOD is the LOD
calculated from NPL Z sores according to Kong and Cox (1997). IC the information content and is a measure of the
probability that the IBD status at a certain locus can be determined for a given pairs of relatives. Alpha a measure of
the locus heterogeneity that indicates the proportion of families with alleles linked to disease at a certain locus.
HLOD estimate of the heterogeneity LOD score. Delta measure of allele sharing among affected individuals within
pedigrees. Empirical P value estimated probability of having a score by chance that is at least as large as the observed
one, after correction for multiple comparisons
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a CNV in the child or that the father has two identical haplotypes with the exception
of the presence of the CNV.
Similarly, in pedigree 29–0209 the son (29–10643) has inherited the same haplotype
as his sister from the father, but no CNV was detected despite being present in both
the father and the sister. This could be explained either by a double crossover or by us
failing to detect the CNV. In family 26–5011 the haplotype with the CNV was only
transmitted to one of the affected children. In family 20–1049 the CNV was
transmitted from the untyped father (20–10855) to a child with diagnosis under ASM2
but not to the sibling with diagnosis under ASM1.
Fig. 3 CNV-weighted linkage analysis at 19q13. Linkage scores and CNV-weighted linkage scores are illustrated
relative to UCSC genes and structural variations in Data Base of Genomic Variation (DGV). The plotted red linkage
curve represents results of the LOD scores from 5 pedigrees (pedigree-id: 29–0209, 29–0174, 26–5011, 20–1049
and 12–330), consisting of 12 individuals (ind-id: 29–10642, 29–10656, 29–10528, 29–10535, 29–10532, 26–50071,
26–50069, 20–10868, 20–10856, 12–11239, 12–11241 and 12–11240) who shared a CNV and which generated
CNV-weighted linkage scores (chr19:48066441–48114839 and chr19:48114839–48157656) that survived correction
for multiple comparisons (empirical P= 0.033). The green vertical line marks the location of the shared CNV from
these 5 families relative to the linkage peak and relative to the UCSC genes. Lower panel displays reported
structural variations from DGV. Color scheme of DGV CNVs; blue: gain, red: loss, purple: inversion, black: unknown,
and brown: both loss and gain. All genomic coordinates are according to NCBI36/hg18
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Fig. 4 (See legend on next page.)
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This prompted us to identify plausible undetected CNVs, by investigating non-QC
data in the entire sample in this region. We observed deletions for three individuals
(11–11113, 11–12163 and 29–10511) in three additional pedigrees (11–130, 11–156
and 29–0172) (Fig. 4b). We further observed that individual 29–10514 has a deletion
adjacent to the region of interest. A haplotype analysis of these three pedigrees revealed
a de novo CNV in pedigree 20–0172 for individual 29–10511 and deletions in families
11–130 and 11–156 that were not transmitted (Fig. 4b) and therefore not included in
our CNV-weighted linkage analysis. From the haplotype analysis it seems unlikely that we
have missed to detect CNVs in this region in other family members of these three families.
Discussion
Linkage analysis
Our genome-scan using 20,123 markers resulted in a high resolution mapping to
identify narrow regions linked to BPD. We performed QC analyses aiming to reduce
influences from markers located in CNV regions and selected informative markers using
an independent study population. We estimated thresholds for suggestive linkage through
simulation according to a well established criteria of Lander and Krygluak 1995 [29] to
obtain robust linkage data. Four loci reached suggestive evidence of linkage to BPD.
The most notable linkage was to chromosome 3p14.1. This signal reached suggestive
linkage in both the non-parametric and parametric dominant models under ASM3, and
is consistent with several previous reports of linkage to BPD [30–32]. Several candidate
genes related with synaptic and other functions of relevance to BPD susceptibility
reside in this region [32]. Of note, one of the suggested genes, MAGI1, has recently been
reported [33] to harbor large structural variation (CNV) in the same BP-pedigree sample
(See figure on previous page.)
Fig. 4 Haplotype analysis of families with CNVs in 19q13. Phasing analysis of genotypes to generate the most
likely haplotype in pedigrees with CNVs on chromosome 19q13, was carried out with the GENEHUNTER
software. Forty-seven markers representing all available markers in this region, spanning a region of 17.04 Mb,
were included for the haplotype analysis. To simplify illustration of results, flanking markers were removed and
only genotypes for 33 markers most proximal to the CNV are depicted, mapping a 6.05 Mb region. The linkage
peak region is marked with a gray window and spans 1.5 Mb. The region with the two adjacent significant
CNV-weighted linkage scores (91,215 bp in size) is illustrated with a gray dashed line. CNVs of duplication are
denoted ‘dupl’, deletions are denoted ‘del’ and the normal state (wild type) are denoted ‘wt’. Haplotypes are
displayed in colors (only for relevant chromosomes) to illustrate inheritance of gain/loss of genomic segments.
The relative genomic region of each CNV is illustrated by separate colored segments. Of note, CNV calling was
made based on a complete set of non-QC filtered sample of both monomorphic and polymorphic probes
whereas analysis of the haplotypes was made using QC filtered polymorphic probes only. In order to retrieve
recombinant mapping of high resolution, all available SNP-markers located within the linkage peak region
were included. Representative gene-id’s are displayed. All genomic coordinates are according to NCBI36/hg18.
a Results of the initial analysis of CNV-weighted linkage scores with 5 pedigrees consisting of 12 individuals with
a shared CNV. In pedigree 29–0174 no DNA was available for individual 29–10665 who was therefore excluded
from the initial CNV-weighted analysis. The CNV status for this individual was revealed in the subsequent
phased haplotype analysis. Moreover, in pedigree 20–1049 the CNV-carriership in 20–10855 was detected using
the subsequent phased haplotype analysis. b Results of the extended analysis to find undetected CNV’s. In our
first attempt to identify undetected CNV’s in this region we manually checked the CNV calling and identified 3
individuals with deletions, 11–11113, 11–112163 and 29–10511, and individual 29–10514 with a deletion in the
adjacent region. Finally, a phased haplotype analysis indicates that the CNV in 29–10511 is a de novo event
and that no transmission of CNV’s occurs in the pedigrees 11–130 and 11–156. This analysis further indicates
deletions in 29–10665 and 20–10855
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as was used in the present study. The MAGI1 gene polymorphism was further validated
in an independent sample of unrelated bipolar, schizophrenia and schizoaffective disorder
cases, and thus, represents an interesting candidate for future studies. The synaptic
function gene, MAGI1, has also been proposed as a putative candidate in a linkage and
expression analysis by Lopez de Lara 2010 [32]. However, it is unlikely that the MAGI1
CNV is the major reason for the observed linkage at 3p14 in our sample since the CNV
reported by Karlsson et al. [33] was only observed in two (11–158 and 11–130) of the 46
BP-pedigrees used in both studies. This argument is supported by the notion that under
the parametric linkage 29 % of the pedigrees are estimated to be linked to this
region (see Table 2). The non-parametric linkage obtained without pedigree 11–158
and 11–130 was as high as 1.56, while it was 1.16 in these two families alone.
Our suggestive linkage to 1q23 in the parametric recessive analysis is consistent with
the model-free linkage analyses reported previously [34, 35]. This locus has also been
linked to schizophrenia [36] which further supports a shared genetic vulnerability
between schizophrenia (SZ) and BPD. There have been several reports of linkage to
10q26.2 [31, 37, 38] where we detected suggestive linkage for the recessive model.
Although chromosome 6 has been a focus for a BPD risk locus [39, 40], none of these
regions overlap with 6q16 reported in our study.
The present study was aimed for a CNV-weighted analysis and apparently several
pedigrees in our sample were not optimal for a linkage analysis. Since the number and
sizes of pedigrees were small, the number of meioses was limited, leading both to low
power and reducing the ability to pinpoint linkage to a small region. Of note, the same
BP-pedigrees have been included in previous linkage scans of both parametric and
non-parametric models [41] without yielding suggestive linkage in regions overlapping
with those identified in the present study. This notion underlines the profoundly
heterogenetic background of BPD and motivates methods attempting to search for
shared segregating risk loci in a more homogenous sample than in the present study.
CNV-weighted linkage analysis
Based on 2806 CNV segments, which were all found in the general population, the
parametric dominant ASM1 model identified two CNV-weighted linkage scores on
19q13 that remained significant after a 1000-fold simulation including a FWER
correction (empirical P = 0.033). We did not adjust thresholds for significance for the
CNV-weighted linkage analyses according to all tested models. Our CNV-weighted
linkage score on 19q13 would not be significant if all nine models were accounted for
according to Bonferroni’s approach. However, a Bonferroni correction would be too
conservative as the models are correlated (see Fig. 2). Our algorithm identified 12
CNV-carriers in 5 families that contributed to this signal (Fig. 4a). The CNV
polymorphism is located in a region with frequent structural variations and harbors a
gene family encoding the pregnancy-specific glycoprotein (PSG) genes (Fig. 3).
In a series of subsequent analyses we aimed to find possible implications of structural
variation in the PSG gene in vulnerability to BPD as well as to unravel if the CNVs are
inherited or de novo. To do this we analyzed phased haplotypes in the 19q13 region
and manually checked the CNV calling prior to QC filtering. We found that in the 5
BP-pedigrees contributing to the CNV-weighted linkage score on 19q13 under the
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ASM1 model, 9 of 17 were affected (BP-I) but also that 5 of 15 unaffected (i.e. not
classified BP-I) individuals were positive for the CNV, that is, they had a deletion (del) or
duplication (dup) of a chromosomal region that included the CNV-weighted linkage peak.
This indicates that if the CNV is functional in causing risk for BPD it still has incomplete
penetrance, whereas some individuals got BPD due to other reasons.
This observation can also be construed as the CNV having no involvement in the
etiology of BPD. Although this cannot be entirely ruled out, the counter-argument that
nonetheless underscores the involvement of the CNV polymorphism in 19q13 in the
etiology of BPD concerns issues of disease classification. In spite of the fact that this
polymorphism occurs in individuals without disease classification according to ASM1,
they are not classified as never mentally ill. The fact that the CNV deletions and
duplications are not entirely overlapping are most likely due our CNV calling algorithm
based on SNPs, as described in the Additional file 1. Of importance, none of the
suggestive linkage signals or significant CNV-weighted linkage scores occurred in regions
in which families were selected (Additional file 2).
Possible candidate for BPD in 19q13?
Of interest, our result with a significant signal on 19q13 for BPD susceptibility agrees
with previous reports.
First, without implicating a specific gene, Francks et al. [42] detected linkage of 19q13
to both SZ and BPD. The 19q13 locus harbors several putative candidate risk genes for
BPD, e.g. the glycogen synthase kinase 3-α (GSK3A) gene and the glutamate receptor,
ionotropic kainate 5 (GRIK5) gene. The GSK3A protein is homologous to GSK3B, a target
molecule for lithium treatment [43], which has regulatory functions on proteins with a
reported role in BPD susceptibility [44]. Several genes pertaining to the glutamate system
have consistently been associated with BPD [39]. Taken together, there is a strong support
for both the glutamate and the cell growth-maintenance related genes in BPD etiology.
Secondly, Alkelai and collaborators [45] found the CEACAM21 gene in the 19q13
region to associate with SZ. The CEACAM genes, or the carcinoembryonic antigen-
related cell adhesion (CEA) gene family, have several structural and functional similarities
to the PSG genes (OMIM: 109770). Recent results show that the CEA genes are both
brain and immune cell expressed (http://genome.ucsc.edu/). Although the exact molecu-
lar function of these gene products remains elusive, some studies reveal function related
to cell-cell adhesion, innate immune system and signal modulation in various
tissues [46–48]. These lines of results, in parallel to the enrichment of immune
system genes among those associated or linked to BPD [49, 50] suggest a possible
role for the PSG gene in BPD etiology.
Other candidates in this linkage peak region include genes related to neurotrophin [39]
and immune systems [51] (Fig. 3), which is interesting, given that such mechanisms have
been proposed to be involved in the etiology of BPD and other psychiatric disorders.
The mechanisms of the clinical manifestations and phenotypic effects of CNVs are well
documented [52] and include alteration of gene dosage, truncated protein or positional
effects. The latter include a transcription that may be directly controlled by promoters in
the CNV or by alteration of chromatin structure [53]. Of note, regulatory elements have
been identified as far away as 2 Mb from the transcription unit [52, 53].
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Based on these observations we made a bioinformatic search (http://regulome.
stanford.edu/) and screened all available markers in the CNV region for being
transcription factor binding sites. Two markers (rs4802370 and rs7252967) are likely
transcription factor binding sites and linked to expression of the F-box binding
gene (FBXO30). The F-box protein functions as an ubiquitin-ligase and targets the
transcription factor NF-kB [54]. Of interest, the NF-kB pathway has been shown to
be a key regulator of neuroplasticity, neuronal survival and pro-inflammatory status
and thus serves as a one of many etiology correlates to BPD [55, 56].
In a previous study, Karlsson et al. 2012 [33], identified a rare and highly penetrant CNV
which map in the MAGI1 gene. The Karlsson et al. study analyzed the identical dataset as
was used in the present study and reported the MAGI1-CNV in the pedigrees 11–158 and
11–130. Although the polymorphism in theMAGI1 gene in pedigrees 11–158 and 11–130,
reported by Karlsson et al. 2012 [33], was ranked among the 25 strongest candidates in the
CNV-weighted linkage analysis it was not the strongest observation (Additional file 7).
This is explained by the non-overlapping CNV segments between these two families.
Limitations
Although our approach was successful in reducing genetic heterogeneity and evaluating
linkage restricted to regions with shared CNVs there are several limitations in this study.
Firstly, CNVs were called if they were longer than 10 kb. Several lines of evidence
suggest that CNVs shorter than 100 kb are less consistent using SNP-array CNV calling
[57]. Of note, shorter structural variations have gained a great deal of attention for their
role in complex disorders [13, 58]. Thus, for the purpose of not rejecting a priori true
positive CNV segments with a putative role for BPD-vulnerability, shorter segments
were allowed in this study. The CNVs in 19q13 were all longer than 100 kb, except for
one CNV of length 91,215 bp.
Secondly, properties of the algorithm and definition of shared CNVs have
consequences for the final results. It can be argued that sharing of CNVs between more
than two individuals in the same family should be used for identification of CNV with
major implications on susceptibility for BPD. The limited pedigree size prompted us to
set this threshold at two individuals.
Thirdly, the CNV-weighted LOD score method has the potential to highlight
regions where presence of a segregating CNV in pedigrees correlates with a higher
family-wise LOD score. Since this approach simply sums LOD scores across
families with at least two CNVs, but otherwise do not weight the family LOD
scores by the CNV frequencies, CNVs which are strongly correlated with high
LOD scores in a small fraction of pedigrees would rank lower in comparison to
what would be seen for less strongly correlated CNVs found in a large proportion
of pedigrees. It would therefore be of interest in future studies to weight the family
linkage scores in different ways in terms of their family members CNV. In fact,
CNV-weighted linkage analysis is an instance of combined association and linkage
analysis, for which different methods and score functions have been proposed, see
for instance [59–61] and references herein.
Fourthly, in the present study we set the threshold for defining a shared CNV as
being strict overlapping. It is unclear whether this categorization is necessary for it to
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contribute to increased risk for disease [12, 62, 63]. Thus, our study design may
possibly have led to rejection of putative disease causing CNVs.
Lastly, although the PennCNV algorithm reports CNVs with a high power and at a low
false positive rate [64], we cannot exclude that we missed to detect CNVs in our dataset.
In summary, our study provides statistical evidence that a region on 19q13 could be tied
to BPD, which raises the possibility that this region confers risk to BPD for a subsample of
individuals. Still, these results are as yet inconclusive for a specific candidate gene. Further
studies are needed in independent samples in order to confirm the involvement of CNVs at
19q13 in BPD susceptibility and to understand the molecular consequences of such a CNV.
Nonetheless, we conclude that our CNV-weighted linkage approach is a useful tool for
future studies, attempting to address the role of larger structural variants in multifactorial
diseases such as BPD.
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